{"symbol":"LLY","provider":"yahoo-finance","fetchedAt":"2025-12-26T10:22:13.590Z","asOfDate":"2025-12-26","articles":[{"id":"8460af4a-900c-3546-8c89-2c3e621e8deb","title":"Buying This Pharmaceutical Stock Could Make You a Millionaire Retiree","url":"https://finance.yahoo.com/m/8460af4a-900c-3546-8c89-2c3e621e8deb/buying-this-pharmaceutical.html","publisher":"Motley Fool","publishedAt":"2025-12-26T09:30:00.000Z","relatedTickers":[],"mainIdea":"Buying This Pharmaceutical Stock Could Make You a Millionaire Retiree","summary":"Motley Fool: Buying This Pharmaceutical Stock Could Make You a Millionaire Retiree."},{"id":"033d7bf0-85f0-37b7-86e7-80a1d6eb645d","title":"ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly","url":"https://finance.yahoo.com/news/abl-bio-receives-upfront-payment-045500110.html","publisher":"PR Newswire","publishedAt":"2025-12-26T04:55:00.000Z","relatedTickers":["298380.KQ"],"mainIdea":"ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly","summary":"PR Newswire: ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly. ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, announced that ABL Bio will receive a USD 40 million upfront payment for the license, research and collaboration agreement for its Grabody platform, and a USD 15 million equity investment from Eli Lilly and Company (\"Lilly\"). Related tickers mentioned: 298380.KQ."},{"id":"abdf303f-3943-3bca-bb90-a84a0130e56a","title":"Is Eli Lilly Pulling Ahead in the Weight Loss Drug Battle?","url":"https://finance.yahoo.com/m/abdf303f-3943-3bca-bb90-a84a0130e56a/is-eli-lilly-pulling-ahead-in.html","publisher":"Motley Fool","publishedAt":"2025-12-25T17:05:00.000Z","relatedTickers":["NVO"],"mainIdea":"Is Eli Lilly Pulling Ahead in the Weight Loss Drug Battle?","summary":"Motley Fool: Is Eli Lilly Pulling Ahead in the Weight Loss Drug Battle?. Related tickers mentioned: NVO."}]}
